Aripiprazole Tablet
Product Images NDC 70518-3090

12 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-3090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Aripiprazole Structure (Aripiprazole Fig8)
Chemical structure of the active ingredient Aripiprazole, showing its molecular arrangement with chlorine atoms, nitrogen, and oxygen.*
FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)
A pharmacokinetic chart showing the fold change and 90% confidence intervals for Aripiprazole exposure (AUC and Cmax) when administered with various interacting drugs including CYP3A4 inhibitors and inducers, CYP2D6 inhibitors, gastric acid blockers, and other drugs like valproate, lithium, and lorazepam. The horizontal axis shows change relative to a reference without interacting drug.*
FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)
A pharmacokinetic chart showing the fold change and 90% confidence interval of Dehydro-Aripiprazole exposure metrics (AUC and Cmax) relative to reference without interacting drugs. The chart compares the effects of CYP3A4 and CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs such as valproate, lithium, and lorazepam on Aripiprazole metabolism.*
FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)
A forest plot illustrating pharmacokinetic (PK) interactions showing fold change and 90% confidence intervals for various drugs relative to a reference without interacting drug. The x-axis represents change relative to reference (0.5 to 3.0), and the y-axis lists drugs including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine (with O-desmethylvenlafaxine), and escitalopram. Different PK parameters such as DM/DR, AUC, Cmax, and INR are indicated.*
FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)
A pharmacokinetic chart titled "Aripiprazole Fold Change and 90% CI" comparing the change relative to reference for AUC and Cmax parameters under various conditions including CYP2D6 metabolizer status, gender, age categories, hepatic impairment levels, and severe renal impairment. Confidence intervals are shown for each comparison.*
FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)
A forest plot chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' displaying pharmacokinetic changes (AUC and Cmax) relative to reference under different conditions including CYP2D6 metabolism, gender, age, hepatic impairment, and severe renal impairment. Each condition is shown with corresponding effect size points and 90% confidence intervals on a horizontal axis representing change relative to reference.*
FDA Label Image

Aripiprazole-graph-a (Aripiprazole Graph A)

Aripiprazole-graph-a (Aripiprazole Graph A)
A line graph showing the proportion with relapse over 182 days from randomization, comparing Aripiprazole and Placebo groups. The y-axis represents the proportion with relapse, ranging from 0 to 1.0, and the x-axis shows days from randomization, with the number of subjects at risk listed below. The graph shows a lower relapse proportion for the Aripiprazole group compared to Placebo over time.*
FDA Label Image

Aripiprazole-fig-16-a (Aripiprazole Fig 16 A)

Aripiprazole-fig-16-a (Aripiprazole Fig 16 A)
A Kaplan-Meier curve comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The chart includes numbers of subjects at risk at various time points for both groups, with Aripiprazole showing a lower relapse rate than placebo.*
FDA Label Image

Aripiprazole-fig-17-a (Aripiprazole Fig 17 A)

Aripiprazole-fig-17-a (Aripiprazole Fig 17 A)
A line graph showing the proportion of subjects with relapse over time in days from randomization, comparing Aripiprazole with placebo. The y-axis represents the proportion with relapse, and the x-axis shows days from randomization. A table below the graph lists the number of subjects at risk for each group at various time points.*
FDA Label Image

Aripiprazole-fig-18 (Aripiprazole Fig 18)

Aripiprazole-fig-18 (Aripiprazole Fig 18)
A line graph depicting the least-squares mean change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo, showing changes in tic scores across the treatment period.*
FDA Label Image

Mm1 (Aripiprazole 2mg 70518 3090 00)

Mm1 (Aripiprazole 2mg 70518 3090 00)
Aripiprazole Tablet 2 mg oral tablets in a 30-count package. The label shows the proprietary and generic name, strength, quantity, and NDC number 70518-3090-00. It is repackaged by RemedyRepack Inc., with storage instructions and a QR code also visible on the label.*
FDA Label Image

Mm2 (Aripiprazole 2mg 70518 3090 01)

Mm2 (Aripiprazole 2mg 70518 3090 01)
Aripiprazole Tablet 2 mg oral tablets, package containing 30 tablets. The label includes the NDC number 70518-3090-01, repackaged by RemedyRepack Inc. in Indiana, PA. Storage instructions indicate to keep out of reach of children and store at 20-25°C with permitted excursions. Manufacturer listed as Ascend Labs, LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.